Amycretin (5 mg) Dosage Protocol
A unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk, investigated in early trials for appetite suppression and weight loss — an investigational compound, not an approved drug.
Single peptide activating both the GLP-1 and amylin receptors — two appetite-regulating pathways in one molecule.
Once-weekly subcutaneous in trials, titrated slowly from ~0.3 mg upward; presented as research reference, not prescription.
Investigational; phase 1b/2a showed up to ~22% weight loss over 36 weeks. Advancing to Phase 3, not FDA-approved.
Quickstart Highlights
Amycretin is a unimolecular GLP-1 and amylin receptor agonist — a single engineered peptide that activates two appetite-regulating pathways at once, developed by Novo Nordisk in both a once-weekly subcutaneous form and a once-daily oral tablet[1]. In the published research it is investigated for appetite suppression, body-weight reduction and glycemic control, and its early data have drawn attention as a potential “next-generation” obesity candidate[2].
Amycretin is investigational and not approved by the FDA or any regulator; the figures below reflect early-phase trial conventions and are provided strictly for research and educational reference — not medical advice or a recommendation to self-administer. Grey-market “amycretin” is unverified and may not be the genuine molecule.
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers. Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →Mix & measure Amycretin · 5 mg
Supplies Needed
Everything a documented subcutaneous protocol relies on. Nothing here is exotic — sterile technique and accurate small-volume measurement matter far more than any single tool, especially at the low starting doses.
Protocol Overview
At 2.5 mg/mL a single 5 mg vial holds roughly 2 mL of usable solution — enough for a multi-week starter titration but only a couple of doses once you reach a 2.5 mg weekly maintenance level. Plan supply around your target dose rather than assuming a fixed number of weeks per vial.
Because the dose changes during titration, recalculate your syringe volume at each step rather than reusing a fixed mark.
Dosing Protocol
A conservative reference titration for a 5 mg vial, converted to U-100 units at 2.5 mg/mL. Trial maintenance arms went considerably higher (5 mg and 20 mg weekly) — the table below stays within what a single small research vial supports.
| Phase / Week(s) | Weekly Dose | Volume (U-100 units / mL) |
|---|---|---|
| Weeks 1–2 | 0.5 mg (1× weekly) | 20 units (0.20 mL) |
| Weeks 3–4 | 1.0 mg (1× weekly) | 40 units (0.40 mL) |
| Weeks 5–6 | 1.5 mg (1× weekly) | 60 units (0.60 mL) |
| Weeks 7+ | 2.5 mg (1× weekly) | 100 units (1.00 mL) |
Why Amycretin draws research interest
These are the directions researchers and the peptide community most often explore Amycretin for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.
Weight reduction
Investigated for substantial body-weight reduction — up to ~22% over 36 weeks in early subcutaneous trials — via combined GLP-1 and amylin appetite signaling.
Glycemic control
Studied in type-2 diabetes, where it reduced HbA1c alongside weight loss in phase 2 research.
Dual-mechanism design
Of interest as a unimolecular way to reach amylin-plus-GLP-1 combination benefits in a single long-acting peptide.
Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.
Add 2.0 mL bacteriostatic water to one 5 mg vial → 2.5 mg/mL (2,500 mcg/mL).
Reference titration 0.5 → 2.5 mg once weekly; trials escalated far higher (maintenance arms up to 20 mg).
Subcutaneous, once weekly on the same day; rotate abdomen / thigh / upper-arm sites.
Investigational (Phase 3 initiating) — promising early human data, but no approval and no long-term safety record.
Dosing & Reconstitution Guide
Like other incretin-based agents, amycretin is titrated slowly because gastrointestinal tolerability — not peak effect — is the limiting factor. In the trials the dose was stepped up gradually over many weeks so the gut could adapt.
Standard / Gradual Approach
The subcutaneous phase 1b/2a program escalated amycretin from a 0.3 mg starting dose toward separate maintenance targets of 1.25 mg, 5 mg or 20 mg once weekly, with weight loss increasing across the dose range[1]. A conservative reference titration for a 5 mg vial steps up about every two weeks and holds at any level where side effects are pronounced. Reconstituted at 2.5 mg/mL, each 0.5 mg increment equals 0.20 mL (20 units on a U-100 syringe).
Reconstitution Steps
Reconstitution is identical to other lyophilized peptides — a small diluent volume keeps a small-milligram vial physically sensible.
- ▪Sanitize: Swab the vial stopper and the bacteriostatic-water vial with fresh alcohol pads and let them dry.
- ▪Add diluent slowly: Draw 2.0 mL bacteriostatic water and let it run down the inside wall of the vial — do not spray it directly onto the powder.
- ▪Dissolve gently: Swirl; do not shake. The solution should clear within a minute or two.
- ▪Store: Label with the date and refrigerate at 2–8 °C; the reconstituted vial holds ~2.5 mg/mL.
Storage Instructions
Store the lyophilized vial in the freezer or refrigerator away from light until reconstitution.
After reconstitution, keep the vial refrigerated at 2–8 °C and use within the bacteriostatic-water window (commonly cited as up to ~28 days). Discard if the solution becomes cloudy or discolored.
Important Notes
Practical points that keep weekly administration consistent and reduce avoidable side effects.
- ▪Titrate, don’t rush: Nausea, fullness and constipation are dose-related and eased over time in the trials — holding a step longer is preferable to pushing through[1].
- ▪Once weekly: The subcutaneous form is dosed once weekly; there is no basis in the research for daily subcutaneous dosing or for doubling up after a missed dose.
- ▪Sterile technique: Fresh U-100 syringe each time, straight into a puncture-proof sharps container afterward.
- ▪Investigational, unknown long-term safety: Amycretin has only early-phase human data and is entering Phase 3[3]; the amylin/GLP-1 drug class also carries the GLP-1 caution around personal/family history of medullary thyroid carcinoma or MEN 2 and pancreatitis. Purity of grey-market material is unverifiable.
How This Works
Amycretin binds both the GLP-1 receptor and the amylin (calcitonin/CTR-RAMP) receptor from a single molecule. GLP-1 signaling enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and reduces appetite in the brain; amylin signaling adds satiety through the area postrema and nucleus tractus solitarius and further slows gastric emptying[4].
Combining the two pathways is the rationale behind amycretin and related amylin+GLP-1 combinations: in earlier work the addition of amylin receptor agonism enhanced the weight loss seen with GLP-1 alone, and amycretin packages both agonisms into one long-acting peptide[2].
Lifestyle Factors
In the trials that define this molecule, incretin agents are studied alongside a reduced-calorie diet and increased physical activity — the pharmacology supports behavior change rather than replacing it.
Adequate hydration and protein intake are commonly discussed for managing appetite suppression and preserving lean mass; smaller, slower meals reduce the nausea that comes with delayed gastric emptying.
Potential Benefits & Side Effects
What the early-phase human literature reports for the investigational compound; this is not equivalent to a prescribed, supervised course, results were from small trials, and individual outcomes vary.
Reported Effects
- ▪Weight reduction: Once-weekly subcutaneous amycretin produced up to roughly 22% mean weight loss over 36 weeks versus placebo across the dose range in the phase 1b/2a study[1].
- ▪Glycemic control: A separate phase 2 trial reported significant weight loss and HbA1c reduction in people with inadequately controlled type-2 diabetes[5].
- ▪Appetite & satiety: Reduced hunger and earlier fullness are the expected pharmacology from dual GLP-1 + amylin signaling.
- ▪Dual mechanism interest: The unimolecular design is being studied as a way to reach amylin+GLP-1 combination benefits in a single molecule[6].
Common Side Effects
- ▪Gastrointestinal: Nausea, vomiting, diarrhea and constipation were the most common effects and were dose- and titration-related, mostly mild-to-moderate.
- ▪Appetite loss & hydration: Strong appetite suppression can reduce food and fluid intake — a practical caution during titration.
- ▪Class cautions: As a GLP-1/amylin agent it inherits GLP-1-class considerations (gallbladder events, rare pancreatitis, thyroid C-cell contraindication in the class).
- ▪Unknowns: Long-term safety, durability and rare risks are not yet established for this investigational molecule.
Injection Technique
Subcutaneous injection technique is identical to insulin. Accuracy and site rotation matter more than speed, especially at low starting volumes.
Pre-Injection Preparation
- ▪Wash hands; let the refrigerated vial come toward room temperature to reduce sting.
- ▪Swab the stopper and injection site; let the alcohol dry fully.
- ▪Draw your current titration volume into a fresh U-100 syringe and tap out air bubbles.
Injection Procedure
- ▪Pinch a skinfold at the chosen site (abdomen, outer thigh or back of the upper arm).
- ▪Insert the needle at 45–90° and inject the solution at a steady, even pace.
- ▪Withdraw and apply light pressure with a clean swab — do not rub.
Post-Injection Care
- ▪Drop the used syringe straight into a puncture-proof sharps container.
- ▪Rotate sites week to week to avoid local irritation or lipohypertrophy.
- ▪Return the vial to the refrigerator promptly.
Recommended Source
For high-purity research peptides, we point researchers to Prime Lab Peptides for Amycretin (5 mg Vial).
Why Prime Lab Peptides?
- ▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.
- ▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
- ▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
- ▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
- ▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
References
- 1
The Lancet — Amycretin subcutaneous phase 1b/2a (Dahl et al., 2025)Dahl K, Toubro S, Dey S, et al. Randomised, controlled phase 1b/2a study of once-weekly subcutaneous amycretin; up to ~22% weight loss over 36 weeks.
- 2
The Lancet — GLP-1 and amylin receptor multiagonism with amycretin (Comment)Linked commentary on the rationale for combining GLP-1 and amylin agonism in a single molecule for obesity management.
- 3
Novo Nordisk — Amycretin advancing to Phase 3 (press release)Company announcement that both oral and subcutaneous amycretin are advancing to Phase 3 based on the Lancet-published early data.
- 4
Amylin Revisited: A 5-Year Perspective (PMC review)Review of amylin physiology and amylin receptor agonism — area postrema/NTS satiety signaling and combination with GLP-1.
- 5
Novo Nordisk — Phase 2 amycretin in type-2 diabetes (BioSpace)Phase 2 trial reporting significant weight loss and HbA1c reduction in inadequately controlled type-2 diabetes.
- 6
Novo Nordisk — Subcutaneous and oral amycretin data at ADA 2025 / The LancetCompany release summarizing the subcutaneous and oral amycretin datasets published in The Lancet and presented at ADA 2025.
Amycretin — frequently asked questions
How do I reconstitute a 5 mg vial of Amycretin?
Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units.
How much bacteriostatic water should I add to Amycretin?
There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units.
What do the "units" on an insulin syringe mean?
On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand.
How should I store Amycretin after mixing?
Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product.
How many doses does a 5 mg vial of Amycretin provide?
Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose.
Is Amycretin approved for human use?
No. Amycretin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.
New protocols & dosing updates
Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.